Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Sun Pharma Advanced Research Company Ltd.

Sun Pharma Adv. Res

₹ 0.00

0.00 (0.00)%

Business Support

Small-cap - With a market cap of ₹67.83 Cr.

EX-Date	Purpose
12 05 2021	Inter alia, to consider and evaluate proposals for raising of funds in one or more tranches by way of issue of Equity Shares or Securities/ Warrants convertible into Equity shares of the Company, through permissible modes including by way of Preferential Issue, subject to the receipt of necessary approvals.
17 05 2021	Audited Results
26 07 2021	Quarterly Results
01 09 2021	SUN PHARMA ADVANCED RESEARCH COMPANY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/09/2021 ,inter alia, to consider and approve / evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.
01 11 2021	Quarterly Results
04 02 2022	Quarterly Results
17 05 2022	Audited Results
08 08 2022	Quarterly Results & Inter alia, to consider and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals.531433 Sungold Capital Ltd. 09/08/2022 Quarterly Results
07 11 2022	Quarterly Results
13 02 2023	Quarterly Results
22 05 2023	Audited Results Inter alia, to consider and approve and evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals
22 05 2023	Audited Results
07 08 2023	Quarterly Results
06 11 2023	Quarterly Results
05 02 2024	Quarterly Results
04 11 2024	Quarterly Results
10 02 2025	Quarterly Results
19 05 2025	Quarterly Results & Audited Results
10 11 2025	Quarterly Results
14 01 2026	Issue Of Warrants & Employees Stock Option Plan
09 02 2026	Quarterly Results
18 05 2026	Audited Results

News

20-MAY-2026

SPARC’s licensing partner receives Complete Response Letter from USFDA

Ocuvex Therapeutics Inc. has received a Complete Response Letter for the PDP-716 New Drug Application

12:00 PM

19-MAY-2026

SPARC turns black in Q4

The total consolidated income of the company increased by many folds at Rs 1,855.02 crore for Q4FY26

02:22 PM

30-APR-2026

SPARC inks pact to sell Priority Review Voucher for $195 million

PRV was granted by the U.S. Food and Drug Administration for the approval of Sezaby indicated for the treatment of neonatal seizures

11:00 AM

03-FEB-2026

SPARC secures Priority Review Voucher associated with Sezaby approval

The company intends to utilize the voucher to further accelerate its pipeline

12:59 PM

07-JUL-2025

Sun Pharma Advanced Research incorporates wholly owned subsidiary

The Certificate of Incorporation has been issued by the Ministry of Corporate Affairs, Government of India, on July 5, 2025

09:12 AM

17-DEC-2024

SPARC inks binding LoI with UCSF, Tiller

Under the terms of the LoI, SPARC will receive 55% equity stake in Tiller upon execution of LoI

11:08 AM

02-NOV-2023

SPARC enters into agreement for SCD-153 with JHU and IOCB

SPARC had evaluated SCD-153 under a MTA after which it entered into an Option to License Agreement with the licensors

09:52 AM

26-SEP-2023

SPARC incorporates wholly owned subsidiary in Delaware

The main object of the Company is to obtain the services of the WOS which would engage a team of seasoned professionals based in US

02:05 PM

18-NOV-2022

SPARC, Sun Pharma get nod for SEZABY from USFDA

With this approval, SEZABY becomes the first and only product specifically indicated in the U.S. for the treatment of neonatal seizures in term and preterm infants

11:50 AM

09-NOV-2022

SPARC, Sun Pharmaceutical ink licensing agreement

The companies have inked licensing agreement for commercialization of benzyl alcohol and propylene glycol-free phenobarbital sodium powder for injection in the United States

03:00 PM